Table 2 Characteristics of the patients, according to the presence of steatosis.
From: The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
Characteristic | Steatosis Training Group | Steatosis Validation Group 1 – HCV before treatment | ||||
|---|---|---|---|---|---|---|
|  | < 5%, n = 170 | ≥ 5%, n = 140 | P value | No, n = 126 | Yes, n = 45 | P value |
Demographics | Â | Â | Â | Â | Â | Â |
Age at biopsy, years | 46.7 (12.4) | 51.8 (12.1) | 0.0004 | 43.7 (7.3) | 45.2 (7.0) | 0.28 |
Male gender | 110 (55%) | 91 (45%) | 0.96 | 81 (64%) | 30 (67%) | 0.77 |
BMI | 24 (4) | 27 (6) | < 0.0001 | 27 (5) | 31 (4) | < 0.0001 |
Biochemical markers | Â | Â | Â | Â | Â | Â |
α2-macroglobulin, g/L | 2.47 (1.00) | 2.30 (1.04) | 0.07 | 3.10 (1.23) | 3.20 (1.24) | 0.50 |
ALT, IU/L | 104 (119) | 115 (108) | 0.02 | 46 (45) | 61 (48) | 0.003 |
AST, IU/L | 83 (204) | 83 (78) | 0.01 | 80 (61) | 88 (43) | 0.01 |
Apolipoprotein A1, g/L | 1.46 (0.34) | 1.42 (0.33) | 0.30 | 1.27 (0.26) | 1.20 (0.24) | 0.18 |
Haptoglobin, g/L | 0.93 (0.60) | 0.96 (0.52) | 0.19 | 0.77 (0.45) | 0.78 (0.44) | 0.84 |
GGT, IU/L | 83 (132) | 147 (226) | < 0.0001 | 72 (85) | 118 (116) | 0.0007 |
Total bilirubin, μmol/L | 14.8 (31.4) | 14.7 (17.8) | 0.47 | 11.0 (5.0) | 11.3 (4.1) | 0.38 |
Glucose mmol/L | 5.1 (3.7) | 5.9 (2.2) | < 0.0001 | 5.2 (0.9) | 6.0 (1.8) | 0.0007 |
Triglycerides, mmol/L | 1.24 (0.95) | 1.88 (1.78) | < 0.0001 | 1.26 (0.72) | 1.72 (1.0) | 0.0008 |
Total cholesterol, mmol/L | 4.8 (1.2) | 5.1 (1.4) | 0.10 | 4.5 (1.0) | 4.4 (1.0) | 0.10 |
FibroTest | 0.40 (0.29) | 0.45 (0.28) | 0.47 | 0.45 (0.26) | 0.53 (0.24) | 0.07 |
SteatoTest | 0.38 (0.21) | 0.62 (0.22) | < 0.0001 | 0.47 (0.21) | 0.70 (0.16) | < 0.0001 |
Characteristic | Steatosis Validation Group 2 – HCV sustained responders | Steatosis Validation Group 3 – Alcoholic liver disease | ||||
|  | No n = 179 | Yes n = 22 | P value | < 5%, n = 4 | ≥ 5%, n = 58 | P value |
Demographics | Â | Â | Â | Â | Â | Â |
Age at biopsy, years | 43.7 (8.1) | 43.1 (7.0) | 0.7 | 38.0 (12.8) | 47 (9.4) | 0.16 |
Male gender | 110 (62%) | 12 (55%) | 0.53 | 2 (50%) | 45 (78%) | 0.21 |
BMI | 26 (4) | 31 (6) | <0.0001 | 22.9 (2.9) | 24.3 (4.2) | 0.49 |
Biochemical markers | Â | Â | Â | Â | Â | Â |
α2-macroglobulin, g/L | 2.08 (0.79) | 1.73 (0.66) | 0.06 | 2.12 (0.53) | 1.81 (0.55) | 0.26 |
ALT, IU/L | 18 (9) | 26 (9) | <0.0001 | 35 (24) | 74 (90) | 0.10 |
AST, IU/L | 23 (9) | 25 (7) | 0.06 | 74 (43) | 58 (90) | 1.00 |
Apolipoprotein A1, g/L | 1.16 (0.28) | 1.07 (0.25) | 0.2 | 1.67 (0.43) | 1.48 (0.49) | 0.49 |
Haptoglobin, g/L | 0.85 (0.41) | 0.94 (0.56) | 0.85 | 1.55 (0.92) | 1.38 (0.62) | 0.85 |
GGT, IU/L | 20 (18) | 28 (14) | 0.0002 | 327 (184) | 323 (323) | 0.41 |
Total bilirubin, μmol/L | 8.9 (4.6) | 8.1 (4.3) | 0.3 | 28.5 (23.4) | 21.1 (19.5) | 0.28 |
Glucose, mmol/L | 5.3 (1.0) | 5.5 (0.8) | 0.16 | 6.5 (2.2) | 5.7 (1.6) | 0.46 |
Triglycerides, mmol/L | 1.49 (0.98) | 2.05 (1.22) | 0.003 | 1.05 (0.51) | 1.96 (3.15) | 0.28 |
Total cholesterol, mmol/L | 5.0 (1.0) | 5.1 (0.9) | 0.51 | 6.0 (1.38) | 5.4 (2.0) | 0.68 |
FibroTest | 0.29 (0.20) | 0.26 (0.19) | 0.46 | 0.43 (0.32) | 0.43 (0.28) | 0.79 |
SteatoTest | 0.32 (0.20) | 0.62 (0.17) | <0.0001 | 0.44 (0.03) | 0.59 (0.26) | 0.21 |